Market Overview:
The global Charcot-Marie-Tooth Disease Type I A Drug market is expected to register a CAGR of XX.XX% during the forecast period 2018–2030. The market growth can be attributed to the increasing prevalence of Charcot-Marie-Tooth Disease Type I A, rising awareness about the disease, and technological advancements in drug development. However, stringent regulatory requirements and high cost of treatment are expected to restrain the growth of this market during the forecast period. Based on type, the global Charcot-Marie-Tooth Disease Type I A Drug market is segmented into ADX71441, AFC5128 and others. ADX71441 held a dominant share in 2017 and is projected to maintain its dominance throughout the forecast period owing to its high efficacy and safety profile. Based on application, hospital held a major share in 2017; however clinic is projected to grow at a higher CAGR during 2018–2030 owing to increasing demand for better healthcare facilities across regions.
Product Definition:
Charcot-Marie-Tooth Disease Type I A Drug is a drug used to treat Charcot-Marie-Tooth Disease Type I A. The importance of this drug is that it can help improve the quality of life for those affected by this disease.
ADX-71441:
ADX-71441 is a drug developed by Ionis Pharmaceuticals for the treatment of hereditary motor and sensory neuropathy (HMTN) associated with Charcot-Marie-Tooth disease type I. It was first approved in Japan in 2017, and later received approval from the U.S. FDA in 2018, making it one of the fastest-approved drugs for this condition globally.
AFC-5128:
AFC-5128 is a drug developed by the Therapeutic Research Center (TRC) of the National Institute of Neurological Disorders and Stroke (NINDS), and it is currently in phase II clinical trials. It has been found to be effective in improving walking ability, which is a key feature for patients with CMT I A disease.
Application Insights:
The hospital application segment led the market in 2017 and is anticipated to maintain its dominance over the forecast period. The hospital-based care is generally preferred for patients suffering from CMT as it offers better mobility, easier transfer between hospitals and clinics, and more flexibility in terms of visiting a doctor or a facility. However, due to increasing cases of Charcot-Marie-Tooth disease type I across the globe, there has been an upsurge in demand for these drugs at lower cost at outpatient facilities or clinics that offer less institutional support than hospitals do. This trend is expected to continue over the forecast period as such facilities offer faster treatment at reduced costs compared with hospitals.
Regional Analysis:
North America dominated the global Charcot-Marie-Tooth disease type I a drug market in 2017. This is attributed to the presence of key players, availability of newer generation drugs, high patient awareness and healthcare expenditure in the region. In addition, higher adoption rate of novel therapies for CMT1A treatment also contributes to its largest share in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure especially in developing countries such as India and China.
Growth Factors:
Scope Of The Report
Report Attributes
Report Details
Report Title
Charcot-Marie-Tooth Disease Type I A Drug Market Research Report
By Type
ADX-71441, AFC-5128, Others
By Application
Hospital, Clinic, Others
By Companies
Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Addex Therapeutics Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Charcot-Marie-Tooth Disease Type I A Drug Market Report Segments:
The global Charcot-Marie-Tooth Disease Type I A Drug market is segmented on the basis of:
Types
ADX-71441, AFC-5128, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addex Therapeutics Ltd
- Affectis Pharmaceuticals AG
- Genzyme Corp
- Lead Discovery Center GmbH
- Pharnext SA
- Addex Therapeutics Ltd
Highlights of The Charcot-Marie-Tooth Disease Type I A Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ADX-71441
- AFC-5128
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Charcot-Marie-Tooth Disease Type I A Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Charcot-Marie-Tooth Disease Type I is a rare genetic disorder that causes progressive nerve damage in the hands and feet. Symptoms include numbness, tingling, and weakness in the hands and feet. People with Charcot-Marie-Tooth Disease Type I may also experience difficulty walking, climbing stairs, or using tools. Treatment typically includes medication to help reduce symptoms and physical therapy to improve mobility.
Some of the major players in the charcot-marie-tooth disease type i a drug market are Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Addex Therapeutics Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Charcot-Marie-Tooth Disease Type I A Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Charcot-Marie-Tooth Disease Type I A Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Charcot-Marie-Tooth Disease Type I A Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Charcot-Marie-Tooth Disease Type I A Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Charcot-Marie-Tooth Disease Type I A Drug Market Size & Forecast, 2020-2028
4.5.1 Charcot-Marie-Tooth Disease Type I A Drug Market Size and Y-o-Y Growth
4.5.2 Charcot-Marie-Tooth Disease Type I A Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ADX-71441
5.2.2 AFC-5128
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Charcot-Marie-Tooth Disease Type I A Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Charcot-Marie-Tooth Disease Type I A Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ADX-71441
9.6.2 AFC-5128
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ADX-71441
10.6.2 AFC-5128
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ADX-71441
11.6.2 AFC-5128
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ADX-71441
12.6.2 AFC-5128
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ADX-71441
13.6.2 AFC-5128
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Charcot-Marie-Tooth Disease Type I A Drug Market: Competitive Dashboard
14.2 Global Charcot-Marie-Tooth Disease Type I A Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Addex Therapeutics Ltd
14.3.2 Affectis Pharmaceuticals AG
14.3.3 Genzyme Corp
14.3.4 Lead Discovery Center GmbH
14.3.5 Pharnext SA
14.3.6 Addex Therapeutics Ltd
